Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 3:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 5,231 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Infection Clear all
Withdrawn Phase 2 Interventional

Gentian Violet Treatment for Hidradenitis Suppurativa

NCT04388163
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Gentian Violet
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 31, 2026, 3:02 AM EDT
Terminated Phase 1 Interventional

Micafungin Lock Therapy

NCT00809887
View directory record Official record
Conditions
Catheter-Related Fungal Infections
Interventions
Micafungin lock therapy
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
6 Months to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2008 · Synced Oct 31, 2026, 3:02 AM EDT
Recruiting Phase 3 Interventional

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.

NCT06925321
View directory record Official record
Conditions
Invasive Mold Infections
Interventions
Fosmanogepix IV infusion, Standard of care antifungal therapy, Fosmanogepix oral tablet
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
20
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 31, 2026, 3:02 AM EDT
Completed No phase listed Observational

Northern Colorado COVID-19 Biobank

NCT04603677
View directory record Official record
Conditions
Covid19
Interventions
Not listed
Lead sponsor
Colorado State University
Other
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
4
States / cities
Fort Collins, Colorado • Greeley, Colorado • Loveland, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 31, 2026, 3:02 AM EDT
Completed Not applicable Interventional

A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection

NCT00000919
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine/Zidovudine, Ritonavir, Hydroxyurea, Abacavir sulfate, Amprenavir, Nelfinavir mesylate, Efavirenz, Lamivudine, Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
63
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2012 · Synced Oct 31, 2026, 3:02 AM EDT
Terminated Not applicable Interventional

Treatment of Chronic Cryptosporidiosis in AIDS Patients

NCT00001128
View directory record Official record
Conditions
Cryptosporidiosis, HIV Infections
Interventions
Interleukin-12, Paromomycin sulfate, Azithromycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Oct 31, 2026, 3:02 AM EDT
Completed Phase 2 Interventional Results available

MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)

NCT03217136
View directory record Official record
Conditions
Complicated Intra-Abdominal Infection
Interventions
Ceftolozane/Tazobactam, Metronidazole, Meropenem, Placebo for Metronidazole
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
7 Days to 17 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Los Angeles, California • Orange, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 31, 2026, 3:02 AM EDT
Completed No phase listed Observational

Evaluation of Accuracy and Ease of Use of the FilmArray™ Respiratory Panel (RP EZ) in a CLIA-Waived Clinical Setting

NCT02232711
View directory record Official record
Conditions
Upper Respiratory Infections
Interventions
Not listed
Lead sponsor
BioFire Diagnostics, LLC
Industry
Eligibility
Not listed
Enrollment
1,082 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
San Diego, California • St Louis, Missouri • Galveston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2015 · Synced Oct 31, 2026, 3:02 AM EDT
Completed Phase 1Phase 2 Interventional

Adaptive Phase I HCV Study With Nucleoside Analogue, in Combination With Interferon and Ribavirin

NCT00382798
View directory record Official record
Conditions
Healthy Volunteers, Hepatitis C Virus
Interventions
RO5024048
Drug
Lead sponsor
Pharmasset
Industry
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
7
States / cities
San Francisco, California • Aurora, Colorado • Gainesville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2009 · Synced Oct 31, 2026, 3:02 AM EDT
Completed Not applicable Interventional Results available

Reducing Diagnostic Errors in Primary Care Pediatrics (Project RedDE)

NCT02798354
View directory record Official record
Conditions
Diagnostic Errors
Interventions
Quality Improvement Collaborative
Behavioral
Lead sponsor
Montefiore Medical Center
Other
Eligibility
26 Years and older
Enrollment
13,853 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Elk Grove Village, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Oct 31, 2026, 3:02 AM EDT
Completed No phase listed Observational

Retrospective Study of Implants With Peri-implantitis Surgically Treated Using Enamel Matrix Derivative (EMD)

NCT05419102
View directory record Official record
Conditions
Determination of Beneficial Effect of Using Enamel Matrix Derivative During Implant Treatment
Interventions
peri-implantitis surgery with enamel matrix derivative
Procedure
Lead sponsor
North Dallas Dental Health
Other
Eligibility
18 Years to 90 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Oct 31, 2026, 3:02 AM EDT
Completed Phase 3 Interventional

UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects

NCT01979939
View directory record Official record
Conditions
Hepatitis C
Interventions
DCV/ASV/BMS-791325
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
42
States / cities
La Jolla, California • San Diego, California • San Francisco, California + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Oct 31, 2026, 3:02 AM EDT
Not listed Not applicable Interventional

Transmission Reduction Intervention Project

NCT01827228
View directory record Official record
Conditions
HIV
Interventions
Assays, HIV medical care, Social network and venue tracing, Community alerts, Community education, HIV counseling
Other · Behavioral
Lead sponsor
National Development and Research Institutes, Inc.
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 7, 2016 · Synced Oct 31, 2026, 3:02 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa

NCT00712166
View directory record Official record
Conditions
Cystic Fibrosis, Lung Infection, Pseudomonas Aeruginosa
Interventions
AZLI 75 mg three times daily (TID), Placebo three times daily (TID)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
34
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2010 · Synced Oct 31, 2026, 3:02 AM EDT
Withdrawn Not applicable Interventional

Trial of the Use of Doxycycline After Rotator Cuff Repair

NCT02388477
View directory record Official record
Conditions
Rotator Cuff Injury
Interventions
Doxycycline, sugar pill
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 9, 2016 · Synced Oct 31, 2026, 3:02 AM EDT
Recruiting Phase 4 Interventional

The Vancomycin Piperacillin/Tazobactam (VPT) Patient Safety Trial (VPS)

NCT07556107
View directory record Official record
Conditions
Infection, Acute Kidney Injury, Sepsis
Interventions
Piperacillin + Tazobactam, meropenem
Drug
Lead sponsor
Bassett Healthcare
Other
Eligibility
18 Years and older
Enrollment
852 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Worcester, Massachusetts • Omaha, Nebraska • Cooperstown, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 31, 2026, 3:02 AM EDT
Active, not recruiting No phase listed Observational

REMBRANDT: REcovery of the MicroBiome fRom Antibiotics for Dental implanTs

NCT05622721
View directory record Official record
Conditions
Dysbiosis, Clostridium Difficile, Pet-Human Bonding, Antibiotic-Associated Colitis
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 31, 2026, 3:02 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection

NCT03376321
View directory record Official record
Conditions
Influenza A
Interventions
Pimodivir 600 mg, Placebo, SOC Treatment
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
13 Years to 85 Years
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
28
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Fresno, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 31, 2026, 3:02 AM EDT
Completed Phase 2 Interventional Results available

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection

NCT02589847
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
RBX2660, Standard of Care Antibiotics
Biological · Drug
Lead sponsor
Rebiotix Inc.
Industry
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
28
States / cities
Phoenix, Arizona • North Little Rock, Arkansas • Sacramento, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Oct 31, 2026, 3:02 AM EDT
Completed No phase listed Observational

Immune Response in Hypersensitivity Pneumonitis

NCT03873649
View directory record Official record
Conditions
Hypersensitivity Pneumonitis
Interventions
Bronchoscopy with lavage
Other
Lead sponsor
Nabeel Hamzeh
Other
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Oct 31, 2026, 3:02 AM EDT
Terminated Phase 2 Interventional Results available

Dose Ranging Study of the Safety and Efficacy of Orally Administered Lyophilized Fecal Microbiota Product (PRIM-DJ2727) for the Treatment of Recurrent Clostridium Difficile Infection (CDI)

NCT03298048
View directory record Official record
Conditions
Recurrent C. Difficile Infection
Interventions
Low fecal microbiota dose, Mid fecal microbiota dose, High fecal microbiota dose
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 100 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2020 · Synced Oct 31, 2026, 3:02 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

IMPACT: Improving Maternal Postpartum Access to Care Through Telemedicine

NCT06218355
View directory record Official record
Conditions
Postpartum Complication
Interventions
Intensive Education, Enhanced Virtual Care
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
3,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
2
States / cities
Atlanta, Georgia • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 31, 2026, 3:02 AM EDT
Completed Phase 1 Interventional Results available

Vancomycin Powder and Dilute Povidone Iodine Lavage for Infection Prophylaxis in High Risk Total Joint Arthroplasty

NCT04075526
View directory record Official record
Conditions
Osteoarthritis
Interventions
Povidone iodine, Vancomycin powder, Conventional
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
2,129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
14
States / cities
Rancho Mirage, California • Denver, Colorado • Weston, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 31, 2026, 3:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Tedizolid Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis

NCT02620787
View directory record Official record
Conditions
Diabetes, Wound Infection, Healthy Volunteers
Interventions
Tedizolid, Microdialysis Catheter Insertion
Drug · Procedure
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Oct 31, 2026, 3:02 AM EDT